Vilazodone another novel atypical antidepressant drug

Journal of Psychosocial Nursing and Mental Health Services

Volumn 49, Issue 3, 2011, Pages 19-22

  Howland, H ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79952522397     PISSN: 02793695     EISSN: None     Source Type: Journal    
DOI: 10.3928/02793695-20110203-98     Document Type: Article

References (9)

1. Dawson, L.A., & Watson, J.M. (2009). Vilazodone: A 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders. CNS Neuroscience & Therapeutics, 15, 107-117.
2. de Paulis, T. (2007). Drug evaluation: Vilazodone-A combined SSRI and 5-HT1A partial agonist for the treatment of depression. IDrugs, 10, 193-201.
3. Howland, R.H. (2008). Sequenced Treatment Alternatives to Relieve Depression (STAR*D). Part 2: Study outcomes. Journal of Psychosocial Nursing and Mental Health Services, 46(10), 21-24.
4. Howland, R.H. (2010). Therapeutic armamentarium for treating depression. Postgraduate Medicine, 122(4), 66-93. doi:10.3810/pgm.2010.07.2176
5. Khan, A. (2009). Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression. Expert Opinion on Investigational Drugs, 18, 1753-1764.
6. Khan, A., Cutler, A.J., Kadjdaz, D.K., Athanasiou, M., Robinson, D.S., Whalen, H., & Reed, C.R. (2010, May). Efficacy and tolerability of vilazodone, a dual-acting serotonergic antidepressant, in the treatment of patients with major depressive disorder (MDD). Paper presented at the 163rd annual meeting of the American Psychiatric Association, New Orleans, LA.
7. Rickels, K., Athanasiou, M., Robinson, D.S., Gibertini M., Whalen, H., & Reed, C.R. (2009). Evidence for the efficacy and tolerability of vilazodone in the treatment of major depressivedisorder: A randomized, double-blind, placebo-controlled trail. Journal of Clinical Psychiatry, 70, 326-333.
8. Robinson, D.S., Kadjdaz, D.K., Gallipoli, S., Whalen, H., Wamil, A., & Reed, C.R. (2010, May). A 1-year open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder. Paper presented at the 163rd annual meeting of the American Psychiatric Association, New Orleans, LA.
9. Rush, A.J. (2007). Limitations in efficacy of antidepressant monotherapy. Journal of Clinical Psychiatry, 68(Suppl. 10), 8-10.